AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ISIS PHARMACEUTICALS INC. Carlsbad, California As More Drug Patents End, Biotech Stands To Benefit.(THE NEW AMERICA)
Byline: GLORIA LAU
More than $30 billion in drugs made and sold by the world's biggest drug makers will lose patent protection in the next few years.
The entire industry's bottom line undoubtedly will wither as each firm loses market share to their drugs' cheap generic copies, which are allowed on the market once the patents expire.
Even worse, most big drug makers have thin pipelines. To self-medicate, big drug makers are knocking on the doors of tiny biotech firms, fishing for their next billion-dollar products.
One biotech that stands to benefit from the trend is Isis Pharmaceuticals Inc.
In one of the industry's larger deals, Eli Lilly & Co. in August committed more than $200 million to Isis for rights to the smaller firm's lung cancer drug. Isis could get another $300 million in potential royalties.
"This deal with Lilly was a transforming event for our company," said Isis Chief Executive Dr. Stanley Crooke. "It represents a response to the maturation of our Antisense technology. The due diligence we did took a solid year."
- Enrollment Completed in Major Lung Cancer Trial; Trial Involves LY900003 (ISIS...
- Press release article from: PR Newswire January 16, 2002 700+ words
...non-small cell lung cancer in October 2000. In August 2001, Isis exclusively licensed...approximately 75 percent of lung cancer diagnoses in the U.S. Isis Pharmaceuticals...non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM...
- Isis Pharmaceuticals Initiates Phase III Study of ISIS 3521 In Non-Small Cell...
- Press release article from: PR Newswire October 18, 2000 700+ words
...Phase III trial of ISIS 3521 in non-small cell lung cancer (NSCLC). The...non-small cell lung cancer in the U.S., Europe and Japan. ISIS 3521 is a promising...in non small cell lung cancer. Isis has a broad and...
- Isis Pharmaceuticals Provides Update of Phase I/II Clinical Trial of ISIS 3521...
- Press release article from: PR Newswire November 10, 2000 700+ words
...II data mature, ISIS 3521 with chemotherapy...non-small cell lung cancer," said Dr. Yuen...non-small cell lung cancer. Additionally...effects caused by ISIS 3521. The opportunity...non-small cell lung cancer in the U.S., Europe and Japan. ISIS 3521 is a ...
- ISIS 3521 Continues To Prolong Survival and Time To Disease Progression In...
- Press release article from: PR Newswire May 14, 2001 700+ words
...with non-small cell lung cancer," said Dr. Yuen...alpha, the target for ISIS 3521, is important...additional studies of ISIS 3521 will demonstrate...to help people with lung cancer," said Andrew Dorr, M.D., Isis' Vice President and...
- FDA Grants Isis Pharmaceuticals Fast Track Review Status For Isis 3521 in...
- Press release article from: PR Newswire November 8, 2000 700+ words
...to treat non-small cell lung cancer (NSCLC). Isis began a 600-patient, randomized...side effects attributable to ISIS 3521. Lung cancer is the leading type of cancer...trials in non-small cell lung cancer. Isis has a broad and proprietary...
- Isis Presents Data on Cancer Drugs at ASCO Conference - Highlights Isis 3521 in...
- Press release article from: PR Newswire May 22, 2000 700+ words
...to initiate a Phase III trial of ISIS 3521 in non-small cell lung cancer later this year. Dr. Alan Yuen...large-scale pivotal trial of ISIS 3521 in non-small cell lung cancer later this year. ISIS 3521 has the potential to significantly...
- ISIS 3521 Maintains Favorable Prolonged Survival and Strong Overall Response...
- Press release article from: PR Newswire October 30, 2001 700+ words
...with non-small cell lung cancer (NSCLC), according...updated study results of ISIS 3521 in combination with...We are hopeful that ISIS 3521 may represent a...with non-small cell lung cancer." Data from a Phase I clinical trial of ISIS 3521 in combination with...
- ISIS STARTS PHASE III OF ISIS 3521 FOR NON-SMALL-CELL LUNG CANCER.(Brief...
- Magazine article from: BIOWORLD Today Willett, Matthew October 19, 2000 700+ words
Isis Pharmaceuticals Inc...pivotal Phase III trial of ISIS 3521 for non-small-cell lung cancer in combination with the...IV non- small-cell lung cancer, a survival rate more...median survival rate. ISIS 3521, an antisense protein...
